<DOC>
	<DOCNO>NCT00032175</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know gemcitabine effective without capecitabine treat pancreatic cancer . PURPOSE : Randomized phase III trial compare effectiveness gemcitabine without capecitabine treat patient locally advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine With Without Capecitabine Treating Patients With Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare 1-year survival rate patient locally advance metastatic pancreatic cancer treat gemcitabine without capecitabine . - Compare median 2-year survival rate objective response rate patient treat regimen . - Compare toxicity regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord disease stage ( locally advance vs metastatic ) performance status ( 0 1 v 2 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive gemcitabine IV 30 minute day 1 , 8 , 15 oral capecitabine twice daily day 1-21 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive gemcitabine IV 30 minute day 1 , 8 , 15 , 22 , 29 , 36 , 43 first course . After 1-week rest period , patient receive gemcitabine IV 30 minute day 1 , 8 , 15 . Subsequent course repeat every 28 day 4 course absence disease progression unacceptable toxicity . Quality life assess baseline , every 3 month 1 year , annually thereafter . Patients follow every 3 month . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 508 patient ( 254 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm ductal adenocarcinoma pancreas Locally advance metastatic disease amenable curative surgical resection Macroscopic residual disease prior resection histological confirmation allow Unidimensionally measurable disease No intracerebral metastasis meningeal carcinomatosis PATIENT CHARACTERISTICS : Age : Over 18 Performance status : WHO 02 Life expectancy : More 3 month Hematopoietic : WBC great 3,000/mm3 Neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 2 mg/dL Renal : Creatinine le 2 mg/dL Creatinine clearance great 50 mL/min Cardiovascular : No New York Heart Association class III IV heart disease No uncontrolled angina pectoris Other : No prior malignancy except nonmelanoma skin cancer carcinoma situ cervix No concurrent uncontrolled medical condition No medical psychiatric condition would preclude study No known hypersensitivity fluorouracil No dihydropyrimidine dehydrogenase deficiency No know malabsorption syndromes Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy ( include preoperative adjuvant ) disease No concurrent cytotoxic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy ( include preoperative adjuvant ) disease Surgery : See Disease Characteristics Other : No prior investigational drug ( include preoperative adjuvant ) disease No concurrent investigational drug No concurrent dipyridamole allopurinol No concurrent sorivudine sorivudine analog ( e.g. , brivudine ) ( capecitabine arm )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>duct cell adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>